Table 1.

Baseline patient characteristics of the study population presented as tertiles of serum T50 in stable renal transplants

CharacteristicsRenal transplant recipients Tertiles of T50
Overall n=699Tertile 1 n=231Tertile 2 n=233Tertile 3 n=235P Value
T50 (minutes)286±62<262262–311      >311<0.001a
Demographics
 Age, years53.0±12.853.6±12.753.6±13.051.9±12.60.26
 Male gender, n (%)398 (57)135 (58)128 (55)135 (57)0.73
 Current smoker, n (%)84 (13)31 (15)25 (11)28 (13)0.62
 Current diabetes, n (%)170 (24)62 (27)63 (27)45 (19)0.08
 BMI, kg/m226.7±4.826.9±5.126.8±4.626.2±4.60.27
 Systolic BP, mmHg135.9±17.4136.6±17.9136.0±16.6135.1±17.60.66
 Diastolic BP, mmHg82.5±10.982.7±10.982.5±10.282.4±11.70.95
 Heart rate, bpm68.6±11.969.2±13.068.8±11.667.9±11.10.49
Renal Transplantation
 Transplant vintage, years5.4 [1.9–12.1]6.1 [1.7–12.8]5.3 [2.0–12.3]5.2 [1.8–10.1]0.54
 Living donor, n (%)236 (34)61 (27)77 (34)98 (42)0.002a
 Pre-emptive transplant, n (%)105 (15)28 (12)35 (15)42 (18)0.22
 Dialysis vintage, months27 [9–52]29 [10–55]25 [10–48]25 [8–51]0.22
 HLA mismatches, n2 [1–3]2 [1–3]2 [1–3]2 [1–3]0.50
 Age donor, years42.8±15.641.2±16.243.2±15.343.8±15.20.19
 Acute rejection, n (%)186 (27)69 (30)67 (29)50 (21)0.07
Laboratory measurements
 Hemoglobin, mmol/L8.2±1.18.0±1.18.3±1.18.4±1.0<0.001a
 HbA1c, %6.00±0.836.02±0.886.08±0.895.85±0.690.01a
 eGFR, CKD-EPI (mL/min per 1.73 m2)52.4±20.246.6±20.353.3±19.356.7±19.5<0.001a
 Corrected calcium, mmol/L2.41±0.152.37±0.142.40±0.142.45±0.15<0.001a
 Phosphate, mmol/L0.96±0.211.07±0.240.95±0.170.87±0.18<0.001a
 Magnesium, mmol/L0.95±0.120.93±0.130.95±0.110.98±0.11<0.001a
 PTH, pmol/L9.0 [5.9–14.7]8.7 [5.2–15.9]9.1 [6.2–14.4]9.1 [6.3–14.1]0.48
 Venous pH7.37±0.047.36±0.057.37±0.047.37±0.04<0.001a
 Venous HCO3, mmol/L24.6±3.123.6±3.624.5±2.625.8±2.6<0.001a
 hsCRP, mg/L1.6 [0.7–4.6]1.9 [0.8–6.2]1.5 [0.8–4.4]1.4 [0.6–3.5]0.01a
 Albumin, g/L43.0±3.042.1±3.142.8±2.744.0±2.8<0.001a
 Alkaline phosphatase, U/L67 [54–83]67 [53–84]69 [55–83]66 [51–83]0.21
 Total cholesterol, mmol/L5.0 [4.4–5.8]4.9 [4.2–5.9]4.9 [4.3–5.6]5.2 [4.5–5.8]0.03a
 HDL cholesterol, mmol/L1.3 [1.1–1.6]1.3 [1.1–1.6]1.3 [1.0–1.6]1.3 [1.1–1.7]0.09
 LDL cholesterol mmol/L2.9 [2.3–3.5]2.8 [2.2–3.6]2.9 [2.3–3.4]2.9 [2.5–3.6]0.08
 Triglycerides, mmol/L1.68 [1.25–2.30]1.71 [1.24–2.47]1.67 [1.25–2.23]1.66 [1.24–2.24]0.65
 Albuminuria, mg/24 h40 [11–182]82 [16–300]36 [9–133]25 [9–112]<0.001a
Medication
 Antihypertensives, n (%)616 (88)211 (91)202 (87)203 (86)0.18
 Statins, n (%)371 (53)135 (58)125 (54)111 (47)0.05a
 Calcium supplements, n (%)150 (21)72 (31)47 (20)31 (13)<0.001a
 Vitamin D supplements, n (%)171 (24)73 (32)45 (19)53 (23)0.006a
 Vitamin K antagonists, n (%)78 (11)37 (16)20 (9)21 (9)0.02a
 Prednisone, mg/d10 [7.5–10]10 [7.5–10]10 [7.5–10]10 [7.5–10]0.17
 Calcineurin inhibitors, n (%)400 (57)153 (66)133 (57)114 (49)0.001a
 Proliferation inhibitors, n (%)584 (84)182 (79)202 (87)200 (85)0.05
 Sirolimus, n (%)13 (2)3 (1)4 (2)6 (3)0.69
  • a Differences were tested by ANOVA or Kruskal–Wallis test for continuous variables and with chi-squared test for categorical variables.

  • Data are represented as mean±SD or median [IQR]. BMI, body mass index; HbA1c, glycated hemoglobin; HCO3, bicarbonate; hsCRP, high-sensitivity C-reactive protein.